Q1 Earnings Forecast for Zymeworks Issued By Leerink Partnrs

Zymeworks Inc. (NYSE:ZYME) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Zymeworks in a research note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings per share of ($0.51) for the quarter. The consensus estimate for Zymeworks’ current full-year earnings is ($1.39) per share. Leerink Partnrs also issued estimates for Zymeworks’ Q2 2025 earnings at ($0.59) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($1.09) EPS, FY2026 earnings at ($1.30) EPS and FY2027 earnings at ($1.17) EPS.

A number of other equities research analysts have also weighed in on ZYME. Lifesci Capital began coverage on Zymeworks in a research report on Tuesday, March 11th. They set an “outperform” rating and a $30.00 price objective on the stock. Wells Fargo & Company upped their price objective on Zymeworks from $12.00 to $14.00 and gave the company an “equal weight” rating in a research note on Thursday, December 19th. Citigroup boosted their target price on shares of Zymeworks from $18.00 to $19.00 and gave the stock a “buy” rating in a report on Friday, March 7th. HC Wainwright boosted their price objective on shares of Zymeworks from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Monday, March 10th. Finally, JPMorgan Chase & Co. raised Zymeworks from a “neutral” rating to an “overweight” rating and set a $18.00 target price on the stock in a report on Monday, December 16th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Zymeworks has a consensus rating of “Moderate Buy” and an average target price of $21.00.

Zymeworks Trading Up 3.6 %

Shares of Zymeworks stock opened at $12.79 on Thursday. Zymeworks has a 1-year low of $7.97 and a 1-year high of $17.70. The company has a 50 day moving average of $13.76 and a 200-day moving average of $13.68. The company has a market cap of $889.89 million, a PE ratio of -8.53 and a beta of 1.13.

Insider Buying and Selling at Zymeworks

In other Zymeworks news, insider Paul Andrew Moore sold 21,200 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $14.92, for a total value of $316,304.00. Following the completion of the sale, the insider now directly owns 14,741 shares of the company’s stock, valued at approximately $219,935.72. This represents a 58.99 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Kenneth Galbraith sold 57,291 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $14.92, for a total transaction of $854,781.72. Following the sale, the chief executive officer now owns 47,543 shares of the company’s stock, valued at approximately $709,341.56. The trade was a 54.65 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders purchased 1,507,168 shares of company stock valued at $19,339,774 and sold 89,601 shares valued at $1,336,847. Insiders own 1.92% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in shares of Zymeworks by 0.8% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,945,491 shares of the company’s stock worth $24,416,000 after purchasing an additional 14,604 shares during the period. Intech Investment Management LLC bought a new stake in shares of Zymeworks during the 3rd quarter valued at about $266,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Zymeworks by 0.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 132,798 shares of the company’s stock worth $1,667,000 after purchasing an additional 650 shares in the last quarter. FMR LLC increased its position in shares of Zymeworks by 84.2% in the third quarter. FMR LLC now owns 3,336 shares of the company’s stock worth $42,000 after purchasing an additional 1,525 shares during the last quarter. Finally, Vestal Point Capital LP raised its stake in Zymeworks by 39.8% in the third quarter. Vestal Point Capital LP now owns 615,000 shares of the company’s stock valued at $7,718,000 after purchasing an additional 175,000 shares in the last quarter. Institutional investors own 92.89% of the company’s stock.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.